The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...